9EP Stock Overview
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Enanta Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.20 |
| 52 Week High | US$34.00 |
| 52 Week Low | US$7.50 |
| Beta | 0.49 |
| 1 Month Change | -7.58% |
| 3 Month Change | 16.19% |
| 1 Year Change | -63.47% |
| 3 Year Change | -70.81% |
| 5 Year Change | -84.51% |
| Change since IPO | -6.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9EP | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -19.2% | -4.9% | -1.5% |
| 1Y | -63.5% | -19.9% | 0.9% |
Return vs Industry: 9EP underperformed the German Biotechs industry which returned -19.9% over the past year.
Return vs Market: 9EP underperformed the German Market which returned 0.9% over the past year.
Price Volatility
| 9EP volatility | |
|---|---|
| 9EP Average Weekly Movement | 8.4% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 9EP's share price has been volatile over the past 3 months.
Volatility Over Time: 9EP's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 145 | Jay Luly | www.enanta.com |
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir.
Enanta Pharmaceuticals, Inc. Fundamentals Summary
| 9EP fundamental statistics | |
|---|---|
| Market cap | €263.18m |
| Earnings (TTM) | -€129.98m |
| Revenue (TTM) | €69.23m |
3.8x
P/S Ratio-2.0x
P/E RatioIs 9EP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9EP income statement (TTM) | |
|---|---|
| Revenue | US$73.62m |
| Cost of Revenue | US$0 |
| Gross Profit | US$73.62m |
| Other Expenses | US$211.86m |
| Earnings | -US$138.24m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 06, 2024
| Earnings per share (EPS) | -6.53 |
| Gross Margin | 100.00% |
| Net Profit Margin | -187.77% |
| Debt/Equity Ratio | 98.8% |
How did 9EP perform over the long term?
See historical performance and comparison